18β-Glycyrrhetinic acid (GA) is the aglycone of glycyrrhizin that is a component of Glycyrrhiza, and has several pharmacological actions in the central nervous system. Recently, GA has been demonstrated to reach the brain by crossing the blood-brain barrier in rats after oral administration of a Glycyrrhiza-containing traditional Japanese medicine, yokukansan. These findings suggest that there are specific binding sites for GA in the brain. Here we show evidence that [3H]GA binds specifically to several brain areas by quantitative autoradiography; the density was higher in the hippocampus, moderate in the caudate putamen, nucleus accumbens, amygdala, olfactory bulb, cerebral cortex, thalamus, and mid brain, and lower in the brain stem and cerebellum. Several kinds of steroids, gap junction-blocking reagents, glutamate transporter-recognized compounds, and glutamate receptor agonists did not inhibit the [3H]GA binding. Microautoradiography showed that the [3H]GA signals in the hippocampus were distributed in small non-neuronal cells similar to astrocytes. Immunohistochemical analysis revealed that immunoreactivity of 11β-hydroxysteroid dehydrogenase type-1 (11β-HSD1), a defined molecule recognized by GA, was detected mainly in neurons, moderately in astrocytes, and very slightly in microglial cells, of the hippocampus. These results demonstrate that specific binding sites for GA exist in rat brain tissue, and suggest that the pharmacological actions of GA may be related to 11β-HSD1 in astrocytes. This finding provides important information to understand the pharmacology of GA in the brain.
References
[1]
Takeda S, Ishihara K, Wakui Y, Amagaya S, Maruno M, et al. (1996) Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48: 902–905. doi: 10.1111/j.2042-7158.1996.tb05998.x
[2]
Asl MN, Hosseinzadeh H (2008) Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 22: 709–724. doi: 10.1002/ptr.2362
[3]
Takeuchi H, Jin S, Suzuki H, Doi Y, Liang J, et al. (2008) Blockade of microglial glutamate release protects against ischemic brain injury. Exp Neurol 214: 144–146. doi: 10.1016/j.expneurol.2008.08.001
[4]
Jin S, Takeuchi H, Yawata I, Harada Y, Sonobe Y, et al. (2009) Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exp Med 217: 87–92. doi: 10.1620/tjem.217.87
[5]
Takeuchi H, Mizoguchi H, Doi Y, Jin S, Noda M, et al. (2011) Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One 6: e21108. doi: 10.1371/journal.pone.0021108
[6]
Ulmann A, Menard J, Corvol P (1975) Binding of glycyrrhetinic acid to kidney mineralocorticoid and glucocorticoid receptors. Endocrinology 97: 46–51. doi: 10.1210/endo-97-1-46
[7]
Irie A, Fukui T, Negishi M, Nagata N, Ichikawa A (1992) Glycyrrhetinic acid bound to 11 beta-hydroxysteroid dehydrogenase in rat liver microsomes. Biochim Biophys Acta 1160: 229–234. doi: 10.1016/0167-4838(92)90012-3
[8]
Davidson JS, Baumgarten IM, Harley EH (1986) Reversible inhibition of intercellular junctional communication by glycyrrhetinic acid. Biochim Biophys Res Commun 134: 29–36. doi: 10.1016/0006-291x(86)90522-x
[9]
Hayashi Y, Ishida Y, Inoue T, Udagawa M, Takeuchi K, et al. (2010) Treatment of behavioral and psychological symptoms of Alzheimer-type dementia with Yokukansan in clinical practice. Prog Neuropsychopharmacol Biol Psychiatry 34: 541–545. doi: 10.1016/j.pnpbp.2010.02.016
[10]
Iwasaki K, Satoh-Nakagawa T, Maruyama M, Monma Y, Nemoto M, et al. (2005) A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66: 248–252. doi: 10.4088/jcp.v66n0214
[11]
Monji A, Takita M, Samejima T, Takaishi T, Hashimoto K, et al. (2009) Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 33: 308–311. doi: 10.1016/j.pnpbp.2008.12.008
[12]
Matsuda Y, Kishi T, Shibayama H, Iwata N (2013) Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 28: 80–86. doi: 10.1002/hup.2286
[13]
Ikarashi Y, Iizuka S, Imamura S, Yamaguchi T, Sekiguchi K, et al. (2009) Effects of Yokukansan, a traditional Japanese medicine, on memory disturbance and behavioral and psychological symptoms of dementia in thiamine-deficient rats. Biol Pharm Bull 32: 1701–1709. doi: 10.1248/bpb.32.1701
[14]
Takeda A, Itoh H, Tamano H, Yuzurihara M, Oku N (2008) Suppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient rats. Nutr Neurosci 11: 41–46. doi: 10.1179/147683008x301414
[15]
Kawakami Z, Ikarashi Y, Kase Y (2010) Glycyrrhizin and its metabolite 18β-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytes. Eur J Pharmacol 626: 154–158. doi: 10.1016/j.ejphar.2009.09.046
[16]
Kawakami Z, Ikarashi Y, Kase Y (2011) Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell Mol Neurobiol 31: 1203–1212. doi: 10.1007/s10571-011-9722-1
[17]
Tabuchi M, Imamura S, Kawakami Z, Ikarashi Y, Kase Y (2012) The blood-brain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol 32: 1139–1146. doi: 10.1007/s10571-012-9839-x
[18]
Liu D, Song D, Guo G, Wang R, Lv J, et al. (2007) The synthesis of 18beta-glycyrrhetinic acid derivatives which have increased antiproliferative and apoptotic effects in leukemia cells. Bioorg Med Chem 15: 5432–5439. doi: 10.1016/j.bmc.2007.05.057
[19]
Paxinos G, Watson C. (2007) The rat brain in stereotaxic coordinates. New York: Academic Press.
[20]
Orellana JA, Shoji KF, Abudara V, Ezan P, Amigou E, et al. (2011) Amyloid β-induced death in neurons involves glial and neuronal hemichannels. J Neurosci 31: 4962–4977. doi: 10.1523/jneurosci.6417-10.2011
[21]
Silverman W, Locovei S, Dahl G (2008) Probenecid, a gout remedy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol 295: C761–C767. doi: 10.1152/ajpcell.00227.2008
[22]
Negishi M, Irie A, Nagata N, Ichikawa A (1991) Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta 1066: 77–82. doi: 10.1016/0005-2736(91)90253-5
[23]
Herman JP, Patel PD, Akil H, Watson SJ (1989) Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat. Mol Endocrinol 3: 1886–1894. doi: 10.1210/mend-3-11-1886
[24]
Laird DW (2010) The gap junction proteome and its relationship to disease. Trends Cell Biol 20: 92–101. doi: 10.1016/j.tcb.2009.11.001
[25]
Theis M, S？hl G, Eiberger J, Willecke K (2005) Emerging complexities in identity and function of glial connexins. Trends Neurosci 28: 188–195. doi: 10.1016/j.tins.2005.02.006
[26]
Eskandari S, Zampighi GA, Leung DW, Wright EM, Loo DD (2002) Inhibition of gap junction hemichannels by chloride channel blockers. J Membr Biol 185: 93–102. doi: 10.1007/s00232-001-0115-0
[27]
Hughes SW, L？rincz M, Cope DW, Blethyn KL, Kékesi KA, et al. (2004) Synchronized oscillations at alpha and theta frequencies in the lateral geniculate nucleus. Neuron 42: 253–268. doi: 10.1016/s0896-6273(04)00191-6
[28]
Proulx E, Leshchenko Y, Kokarovtseva L, Khokhotva V, El-Beheiry M, et al. (2006) Functional contribution of specific brain areas to absence seizures: role of thalamic gap-junctional coupling. Eur J Neurosci 23: 489–496. doi: 10.1111/j.1460-9568.2005.04558.x
[29]
Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, et al. (1994) Localization of neuronal and glial glutamate transporters. Neuron 13: 713–725. doi: 10.1016/0896-6273(94)90038-8
[30]
Furuta A, Rothstein JD, Martin LJ (1997) Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J Neurosci 17: 8363–8375.
[31]
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, et al. (2007) Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168–176.
[32]
Lecanu L, Greeson J, Papadopoulos V (2006) Beta-amyloid and oxidative stress jointly induce neuronal death, amyloid deposits, gliosis, and memory impairment in the rat brain. Pharmacology 76: 19–33. doi: 10.1159/000088929
[33]
Leuba G, Vernay A, Zimmermann V, Saini K, Kraftsik R, et al. (2009) Differential damage in the frontal cortex with aging, sporadic and familial Alzheimer's disease. Brain Res Bull 80: 196–202. doi: 10.1016/j.brainresbull.2009.06.009
[34]
Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, et al. (2010) Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging 31: 578–590. doi: 10.1016/j.neurobiolaging.2008.05.015
[35]
Kindy MS, Bhat AN, Bhat NR (1992) Transient ischemia stimulates glial fibrillary acid protein and vimentin gene expression in the gerbil neocortex, striatum and hippocampus. Brain Res Mol Brain Res 13: 199–206. doi: 10.1016/0169-328x(92)90027-9
[36]
Bernal GM, Peterson DA (2011) Phenotypic and gene expression modification with normal brain aging in GFAP-positive astrocytes and neural stem cells. Aging Cell 10: 466–482. doi: 10.1111/j.1474-9726.2011.00694.x
[37]
Hayakawa N, Kato H, Araki T (2007) Age-related changes of astorocytes, oligodendrocytes and microglia in the mouse hippocampal CA1 sector. Mech Ageing Dev 128: 311–316. doi: 10.1016/j.mad.2007.01.005
[38]
Middeldorp J, Hol EM (2011) GFAP in health and disease. Prog Neurobiol 93: 421–443. doi: 10.1016/j.pneurobio.2011.01.005
[39]
Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, et al. (2013) Specific glial functions contribute to schizophrenia susceptibility. Schizophr Bull. in press.
[40]
Cao X, Li LP, Wang Q, Wu Q, Hu HH, et al. (2013) Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med 19: 773–777. doi: 10.1038/nm.3162
[41]
Furman JL, Sama DM, Gant JC, Beckett TL, Murphy MP, et al. (2012) Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 32: 16129–16140. doi: 10.1523/jneurosci.2323-12.2012
[42]
Fujiwara H, Takayama S, Iwasaki K, Tabuchi M, Yamaguchi T, et al. (2011) Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience 180: 305–313. doi: 10.1016/j.neuroscience.2011.01.064
[43]
Mizoguchi K, Shoji H, Tanaka Y, Tabira T (2011) Ameliorative effect of traditional Japanese medicine yokukansan on age-related impairments of working memory and reversal learning in rats. Neuroscience 177: 127–137. doi: 10.1016/j.neuroscience.2010.12.045
[44]
Nishi A, Yamaguchi T, Sekiguchi K, Imamura S, Tabuchi M, et al. (2012) Geissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin 1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansan. Neuroscience 207: 124–136. doi: 10.1016/j.neuroscience.2012.01.037
[45]
Seckl JR (1997) 11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action? Front Neuroendocrinol 18: 49–99. doi: 10.1006/frne.1996.0143
[46]
Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, et al. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri？dinemodel of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145–6150. doi: 10.1073/pnas.0937239100
